Bipolar disorder trials recruiting in Illinois

All Bipolar disorder trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
  NCT07172516 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Illinois: Elgin, Orland Park
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
  NCT06696755 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago, Warrenville
• A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder
  NCT07071532 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Grayslake
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  NCT04777357 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Illinois: Chicago, Naperville, Orland Park
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  NCT07105111 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Naperville
• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
  NCT07140913 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
  NCT06951698 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
  NCT06951711 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
  NCT06740383 · Phase: Not specified · Ages: 18 Years to 40 Years · Sex: All (male and female) · Illinois: Chicago
• CLOZAPINE Response in Biotype-1
  NCT04580134 · Phase: Phase 4 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Illinois: Chicago
• Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
  NCT06372964 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Illinois: Chicago, Elgin
• Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
  NCT07494305 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
  NCT06229210 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Illinois: Naperville
• Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
  NCT07220460 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Elgin
• Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
  NCT05303064 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Illinois: Chicago
• Transition Care for FEP
  NCT07713849 · Phase: Not specified · Ages: 18 Years to 40 Years · Sex: All (male and female) · Illinois: Chicago, Harvey